Jacobson Pharma (2633) and JBM Healthcare (02161) Announce Renewal of Continuing Connected Transactions

Bulletin Express03-06

Jacobson Pharma Corporation Limited (2633) and JBM Healthcare Limited (02161) have jointly announced the renewal of continuing connected transactions through new agreements (the “2026 Framework Agreements”). These agreements will take effect upon the expiry of their existing arrangements on 31 March 2026 and will cover a term from 1 April 2026 to 31 March 2029.

Under the 2026 Logistics Services Agreement, the Jacobson Group will continue providing logistics services to the JBM Group. The annual caps for these services are set at HK$8.00 million, HK$9.00 million, and HK$10.00 million for the years ending 31 March 2027, 2028, and 2029, respectively. Pricing remains based on the Jacobson Group’s cost plus a 10.0% margin.

Meanwhile, the 2026 Manufacturing Services Agreement covers the production of selected generic drugs by the JBM Group for the Jacobson Group. Annual caps for these fees stand at HK$7.00 million, HK$8.00 million, and HK$9.00 million for the years ending 31 March 2027, 2028, and 2029, respectively, determined using manufacturing costs plus a 15.0% margin.

The renewed agreements constitute continuing connected transactions under Chapter 14A of the Listing Rules. Given that the highest applicable percentage ratios for the annual caps exceed 0.1% but remain below 5.0%, the transactions only require reporting, announcement, and annual review, without needing a circular or independent shareholders’ approval. Both boards consider these terms to be fair and reasonable and view the agreements as beneficial to each group’s operational and financial interests.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110013937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110013937","market":"us","top_or_hot":-1,"title":"Jacobson Pharma (2633) and JBM Healthcare (02161) Announce Renewal of Continuing Connected Transactions","media":"Bulletin Express","content":"<p>Jacobson Pharma Corporation Limited (2633) and JBM Healthcare Limited (02161) have jointly announced the renewal of continuing connected transactions through new agreements (the “2026 Framework Agreements”). These agreements will take effect upon the expiry of their existing arrangements on 31 March 2026 and will cover a term from 1 April 2026 to 31 March 2029.</p>\n<p>Under the 2026 Logistics Services Agreement, the Jacobson Group will continue providing logistics services to the JBM Group. The annual caps for these services are set at HK$8.00 million, HK$9.00 million, and HK$10.00 million for the years ending 31 March 2027, 2028, and 2029, respectively. Pricing remains based on the Jacobson Group’s cost plus a 10.0% margin.</p>\n<p>Meanwhile, the 2026 Manufacturing Services Agreement covers the production of selected generic drugs by the JBM Group for the Jacobson Group. Annual caps for these fees stand at HK$7.00 million, HK$8.00 million, and HK$9.00 million for the years ending 31 March 2027, 2028, and 2029, respectively, determined using manufacturing costs plus a 15.0% margin.</p>\n<p>The renewed agreements constitute continuing connected transactions under Chapter 14A of the Listing Rules. Given that the highest applicable percentage ratios for the annual caps exceed 0.1% but remain below 5.0%, the transactions only require reporting, announcement, and annual review, without needing a circular or independent shareholders’ approval. Both boards consider these terms to be fair and reasonable and view the agreements as beneficial to each group’s operational and financial interests.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobson Pharma (2633) and JBM Healthcare (02161) Announce Renewal of Continuing Connected Transactions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobson Pharma (2633) and JBM Healthcare (02161) Announce Renewal of Continuing Connected Transactions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-06 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobson Pharma Corporation Limited (2633) and JBM Healthcare Limited (02161) have jointly announced the renewal of continuing connected transactions through new agreements (the “2026 Framework Agreements”). These agreements will take effect upon the expiry of their existing arrangements on 31 March 2026 and will cover a term from 1 April 2026 to 31 March 2029.</p>\n<p>Under the 2026 Logistics Services Agreement, the Jacobson Group will continue providing logistics services to the JBM Group. The annual caps for these services are set at HK$8.00 million, HK$9.00 million, and HK$10.00 million for the years ending 31 March 2027, 2028, and 2029, respectively. Pricing remains based on the Jacobson Group’s cost plus a 10.0% margin.</p>\n<p>Meanwhile, the 2026 Manufacturing Services Agreement covers the production of selected generic drugs by the JBM Group for the Jacobson Group. Annual caps for these fees stand at HK$7.00 million, HK$8.00 million, and HK$9.00 million for the years ending 31 March 2027, 2028, and 2029, respectively, determined using manufacturing costs plus a 15.0% margin.</p>\n<p>The renewed agreements constitute continuing connected transactions under Chapter 14A of the Listing Rules. Given that the highest applicable percentage ratios for the annual caps exceed 0.1% but remain below 5.0%, the transactions only require reporting, announcement, and annual review, without needing a circular or independent shareholders’ approval. Both boards consider these terms to be fair and reasonable and view the agreements as beneficial to each group’s operational and financial interests.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02161","symbol_name":"健倍苗苗","start_time":0,"source_url":"","article_id":"1110013937","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110013937","pubTimestamp":1772802186,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobson Pharma Corporation Limited (2633) and JBM Healthcare Limited (02161) have jointly announced the renewal of continuing connected transactions through new agreements (the “2026 Framework...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02161":"健倍苗苗"},"translate_title":"雅各臣医药(2633)与健必美医疗(02161)公布续订持续关连交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02161":1},"content_text":"Jacobson Pharma Corporation Limited (2633) and JBM Healthcare Limited (02161) have jointly announced the renewal of continuing connected transactions through new agreements (the “2026 Framework Agreements”). These agreements will take effect upon the expiry of their existing arrangements on 31 March 2026 and will cover a term from 1 April 2026 to 31 March 2029.\nUnder the 2026 Logistics Services Agreement, the Jacobson Group will continue providing logistics services to the JBM Group. The annual caps for these services are set at HK$8.00 million, HK$9.00 million, and HK$10.00 million for the years ending 31 March 2027, 2028, and 2029, respectively. Pricing remains based on the Jacobson Group’s cost plus a 10.0% margin.\nMeanwhile, the 2026 Manufacturing Services Agreement covers the production of selected generic drugs by the JBM Group for the Jacobson Group. Annual caps for these fees stand at HK$7.00 million, HK$8.00 million, and HK$9.00 million for the years ending 31 March 2027, 2028, and 2029, respectively, determined using manufacturing costs plus a 15.0% margin.\nThe renewed agreements constitute continuing connected transactions under Chapter 14A of the Listing Rules. Given that the highest applicable percentage ratios for the annual caps exceed 0.1% but remain below 5.0%, the transactions only require reporting, announcement, and annual review, without needing a circular or independent shareholders’ approval. Both boards consider these terms to be fair and reasonable and view the agreements as beneficial to each group’s operational and financial interests.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110013937","isCrawlerRequest":true}